Rhumbline Advisers Reduces Stock Position in Kenvue Inc. $KVUE

Rhumbline Advisers decreased its position in Kenvue Inc. (NYSE:KVUE) by 1.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,517,574 shares of the company’s stock after selling 51,126 shares during the quarter. Rhumbline Advisers owned about 0.18% of Kenvue worth $57,090,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of KVUE. Cornerstone Planning Group LLC raised its position in shares of Kenvue by 705.2% in the third quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock valued at $25,000 after buying an additional 1,361 shares during the last quarter. NBT Bank N A NY grew its stake in Kenvue by 180.3% in the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock worth $25,000 after acquiring an additional 1,006 shares during the period. Salomon & Ludwin LLC acquired a new position in Kenvue in the 3rd quarter valued at $25,000. Golden State Wealth Management LLC raised its holdings in Kenvue by 150.1% in the 3rd quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock valued at $32,000 after acquiring an additional 1,190 shares during the last quarter. Finally, Trust Co. of Vermont lifted its stake in shares of Kenvue by 50.9% during the 3rd quarter. Trust Co. of Vermont now owns 2,385 shares of the company’s stock worth $39,000 after purchasing an additional 804 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently commented on KVUE shares. Johnson Rice reaffirmed a “neutral” rating on shares of Kenvue in a research report on Tuesday, October 28th. Deutsche Bank Aktiengesellschaft set a $18.00 target price on shares of Kenvue in a report on Friday, October 24th. Jefferies Financial Group downgraded shares of Kenvue from a “buy” rating to a “hold” rating and cut their price target for the stock from $23.00 to $18.00 in a research note on Friday, January 30th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a report on Friday, January 9th. Finally, Zacks Research upgraded Kenvue from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 26th. Four equities research analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $19.46.

Kenvue Stock Up 0.8%

NYSE KVUE opened at $18.70 on Friday. The business has a 50 day moving average price of $17.38 and a two-hundred day moving average price of $17.76. The stock has a market cap of $35.82 billion, a PE ratio of 24.93 and a beta of 0.59. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $25.17. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 25th. Shareholders of record on Wednesday, February 11th will be paid a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a yield of 4.4%. The ex-dividend date is Wednesday, February 11th. Kenvue’s dividend payout ratio (DPR) is 110.67%.

Insider Activity

In related news, Director Jeffrey C. Smith purchased 3,200,000 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The shares were purchased at an average cost of $17.37 per share, with a total value of $55,584,000.00. Following the completion of the acquisition, the director directly owned 27,307,632 shares of the company’s stock, valued at approximately $474,333,567.84. The trade was a 13.27% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.68% of the company’s stock.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.